SARS-CoV-2 Omicron KP.2 spike glycoprotein (None widely established; though often abbreviated as "Omicron spike protein" in literature.)

The SARS-CoV-2 Omicron KP.2 spike glycoprotein is a trimeric viral surface protein and the primary mediator of coronavirus entry into host cells. It functions by binding to the angiotensin-converting enzyme 2 (ACE2) receptor, initiating viral attachment and membrane fusion. The Omicron KP.2 variant harbors numerous spike mutations that remodel both the N-terminal and receptor-binding domains, conferring enhanced immune evasion and altered antigenicity relative to other SARS-CoV-2 variants. This protein is the major target of neutralizing antibodies, therapeutic drugs, and vaccine antigens. Due to ongoing mutations, especially in lineages like Omicron KP.2, continuous monitoring of spike protein structure and function is critical for developing effective therapies and vaccines.

Other names

SARS-CoV-2 spike proteinSpike glycoprotein, SARS-CoV-2S proteinSurface glycoproteinCoronavirus spike protein

Block receptor binding (prevent ACE2 interaction) Inhibit spike-mediated membrane fusion Neutralization by specific antibodies blocking antigenic domains Elicit immune response (as vaccine antigen)